Movement disorder emergencies …

Pichet Termsarasab MD

Movement Disorders

Updated 11.27.2023
Released 01.06.2012
Expires For CME 11.27.2026

Movement disorder emergencies

Author: Pichet Termsarasab MD

See Contributor Disclosures

Editor: Robert Fekete MD

Movement disorder emergencies

In This Article

Quick Link

Introduction

Overview

Movement disorder emergencies refer to neurologic conditions where movement disorders are the main feature. These emergencies develop acutely or subacutely and require immediate medical attention. Failure to promptly diagnose and treat these conditions can lead to significant mortality and even morbidity (30). These include neuroleptic malignant syndrome, parkinsonism-hyperpyrexia syndrome, acute decompensation of parkinsonism, serotonin syndrome, lethal catatonia, dystonic storm, and malignant Tourette syndrome.

Key points

	• Prompt diagnosis and management of movement disorder can reduce morbidity and mortality.
	• The mainstay of movement disorder emergencies involves the cessation of the offending agent combined with aggressive supportive therapy.

Clinical features

A movement disorder emergency is characterized by an acute onset of abnormal movements or the rapid evolution of any movement disorder; the failure to appropriately diagnose and treat the patient can result in morbidity or even mortality. Most movement disorder emergencies evolve over hours to days, prompting the patient to seek immediate medical attention. Neurologists will encounter these patients as consultations in the emergency department, inpatient wards, or intensive care unit (ICU). Early recognition of the syndromes and implementation of appropriate therapy is critical. Therefore, a neurologist should always consider these conditions when approaching patients with an acute onset of or rapidly evolving abnormal movements. Patients should be cared for in a closely monitored setting, with special care if the syndrome occurs during pregnancy or while undergoing anesthesia or surgery. Some patients with movement disorders, such as dystonia, experience respiratory problems associated with dystonic respiratory dysregulation (71) and other respiratory problems (70).

There are minimal epidemiologic data on movement disorder emergencies. Few large-scale randomized studies have been performed to assess the efficacy of the recommended treatment strategies. The mainstay of therapies includes aggressive supportive care and specific treatment such as discontinuation of the offending agent in case of neuroleptic malignant syndrome or serotonin syndrome, or treatment of underlying psychiatric disorders in case of catatonia. Common presenting symptoms include hyperpyrexia, confusion, rigidity, and immobility, with additional disease-specific presentations. It is important to rule out other emergency conditions that can mimic these syndromes as they may require different, specific lifesaving interventions and precautions. The differential diagnosis includes malignant hyperthermia, heatstroke, encephalitis, drug intoxication, thyrotoxicosis, acute porphyria, tetany, akinetic mutism, locked-in syndrome (basilar artery stroke, central pontine myelinolysis), and a variety of movement disorders that can result from acute stroke (72) and other systemic disorders (20; 21). In addition to neuroleptic malignant syndrome, parkinsonism-hyperpyrexia syndrome, acute decompensation of parkinsonism, serotonin syndrome, lethal catatonia, dystonic storm, and malignant Tourette syndrome are discussed in this article.

Neuroleptic malignant syndrome

Neuroleptic malignant syndrome is an iatrogenic disorder resulting from exposure to dopamine (D2) receptor-blocking medications, first described by Delay in the 1960s (24; 120). Neuroleptic malignant syndrome is associated with both typical and atypical neuroleptics, but other medications such as tetrabenazine, sertraline, levomepromazine, prochlorperazine, metoclopramide, droperidol, valproic acid, and promethazine have also been implicated (113; 126). Cases of neuroleptic malignant syndrome have been reported in association with the use of newer-generation antipsychotics, such as lurasidone (87). Neuroleptic malignant syndrome most frequently develops within the first 24 to 48 hours after the introduction of a dopamine receptor blocking agent, although rare cases of neuroleptic malignant syndrome have been reported to occur after long-term stable therapy, adjustment of a dosage, or addition of medications such as antiemetics, donepezil, lithium, and serotonin reuptake inhibitors (80). Young males are at highest risk for developing neuroleptic malignant syndrome (36). The pathogenesis of neuroleptic malignant syndrome is not well understood; however, abrupt alterations in central dopamine transmission and proinflammatory cytokine activation have been suggested as playing a pathogenic role (85). A high index of suspicion is necessary to make the diagnosis of neuroleptic malignant syndrome due to the low incidence rates (0.02% to 3%) (67). When not detected and treated early, the mortality may be as high as 22% (18). Neuroleptic malignant syndrome should be considered in any patient who presents with acute-onset rigidity, altered mental status, fever, and a history of neuroleptic exposure.

Neuroleptic malignant syndrome is a clinical syndrome, commonly presenting with fever, rigidity, and elevated creatine phosphokinase (CPK) with concurrent autonomic dysfunction, altered consciousness, and leukocytosis.

Neuroleptic malignant syndrome

This video demonstrates a woman with neuroleptic malignant syndrome from haloperidol use. She has altered mental status, along with marked rigidity of all extremities and a reduction in global movements. Low-amplitude myoclonic je...

In rare cases, rigidity may not be present (127; 86). A reversible isolated lesion in the splenium of the corpus callosum has been reported (125; 50). Several diagnostic criteria have been proposed, which can indicate a high likelihood of neuroleptic malignant syndrome in the appropriate clinical context (see Table 1) (94). New diagnostic criteria utilizing numerical scoring has been proposed and validated through international consensus, demonstrating an 83.2% sensitivity and 94.6% specificity (37; 39) (see Table 1).

Table 1. Diagnostic Criteria and Associated Clinical Features and Laboratory Findings of Neuroleptic Malignant Syndrome

	(60)	International Expert Consensus Neuroleptic Malignant Syndrome Diagnostic Criteria (37)	Priority Score
Major Criteria	Fever Muscle rigidity Elevated CPK	Exposure to dopamine antagonist, or dopamine agonist withdrawal within the past 72 hours	20
Minor Criteria	Tachycardia Abnormal blood pressure Tachypnea Leukocytosis Diaphoresis Altered mental status	Hyperthermia (> 100.4°F) on at least two occasions, measured orally	18
		Rigidity	17
		Altered mental status	13
		Creatine kinase elevation (four or more times upper limit of normal)	10
		Sympathetic nervous system lability (at least two of the following): (a) Blood pressure elevation (systolic or diastolic 25% or more above baseline) (b) Blood pressure fluctuation (20 mmHg or more diastolic change or 25 mmHg or more systolic change in 24 hours) (c) Diaphoresis (d) Urinary incontinence	10
		Hypermetabolism (increased heart-rate more than 25% above baseline) AND increased respiratory-rate (50% or more above baseline)	5
		Negative work-up for infectious, toxic, metabolic, or neurologic causes	7
Diagnostic requirements	All major criteria AND at least 2 minor criteria must be present	A score of 64 or more out of 100*
*An international multispecialty panel of experts reported the highest concordance rates for 74 or more on independent review of cases (36).

Risk factors for neuroleptic malignant syndrome include psychomotor stress, dehydration, the use of intramuscular deposition of neuroleptics, adjustments of neuroleptic dose and loading rate, or concomitant use of antiparkinsonian drugs and lithium carbonate (77); rarely, this syndrome can occur while on chronic stable neuroleptic therapy (54). Neuroleptic malignant syndrome typically progresses over 48 to 72 hours and lasts 7 to 14 days. Chronic, irreversible medical conditions may complicate recovery, such as renal failure secondary to rhabdomyolysis and respiratory failure secondary to decreased chest wall compliance or aspiration pneumonia (70). Other complications due to immobility such as deep vein thrombosis and pressure ulcers have been reported. The presence of multiorgan failure increases the risk of mortality (77). Long-term neurologic complications include cognitive impairment, specifically executive dysfunction; gait instability and dystonia due to cerebellar and basal ganglia injury joint contracture; sensory disturbance; and residual catatonia (77; 58; 64). Hyponatremia secondary to cerebral salt wasting and the syndrome of inappropriate antidiuretic hormone have been reported with neuroleptic malignant syndrome and may precipitate seizures (59). Risk factors for mortality associated with neuroleptic malignant syndrome are older age, acute respiratory failure at presentation, elevated creatinine kinase level, and mean platelet volume (73; 97).

Early aggressive supportive therapy is the mainstay of care in neuroleptic malignant syndrome, which includes admission to the ICU, discontinuation of causative medication, and treatment with antipyretics and dopaminergic agents, such as levodopa, amantadine, bromocriptine, apomorphine, or other dopamine agonists such as pramipexole, ropinirole, or rotigotine patch (92; 117). Dantrolene, a nonspecific muscle relaxant, reduces muscle rigidity and minimizes rhabdomyolysis (114). Carbamazepine was shown to be effective in treating symptoms in a case report of two patients (112). Introduction of dopamine agonists or levodopa has also been suggested (90; 15). Electroconvulsive therapy can be considered in patients where pharmacotherapy is not successful (118). Treatment should last 7 to 10 days, depending on the half-life of the causative agent, and combination therapy can be effective in reducing symptoms. In patients who require continuation of neuroleptic medication, the same medication can be reintroduced, but no sooner than two weeks after complete recovery. Low doses of low-potency neuroleptics are preferred, and gradual titration with close monitoring is recommended. Neuroleptic malignant syndrome recurrence rates are as high as 33% if the neuroleptic is introduced too quickly (95). For those patients who require immediate treatment of psychosis during this recovery period, electroconvulsive therapy may an effective solution for symptom control (124).

Parkinsonism-hyperpyrexia syndrome

Parkinsonism-hyperpyrexia syndrome is a rare and potentially fatal complication of Parkinson disease. First described in the 1980s, physicians observed this syndrome in patients admitted to the hospital for an abrupt withdrawal or dramatic reduction in dopaminergic medications (known as “levodopa holidays”) (29; 91). Several patients were observed to have an acute onset of fever and rigidity identical in presentation to neuroleptic malignant syndrome, without a history of neuroleptic exposure. Symptoms develop between 18 hours and 7 days, consisting of pyrexia and altered consciousness, followed by autonomic dysfunction. Though typically associated with Parkinson disease, parkinsonism-hyperpyrexia syndrome has been reported in other parkinsonian disorders, such as multiple system atrophy, progressive supranuclear palsy, vascular parkinsonism, and Lewy body dementia (105). The pathophysiology is similar to neuroleptic malignant syndrome. An abrupt reduction of central dopamine in combination with disruption of central and peripheral sympathetic outflow and central serotonin levels has been implicated (74). It has been suggested that severe loss of presynaptic dopaminergic neurons may be associated with increased risk of developing this syndrome (48). Mortality rates as high as 4% have been reported; therefore, it is important to recognize potential risk factors to avoid precipitating this syndrome.

Though levodopa holidays are no longer recommended, patient noncompliance and abrupt changes in medication can still precipitate this condition in the absence of planned withdrawal (27). A common scenario in which aggressive reduction in medications frequently occurs is after deep brain stimulation surgery. Neurologists should be aware of this potentially fatal complication and carefully reduce dopaminergic medications after implantation. It is important to note that deep brain stimulation does not protect against parkinsonism-hyperpyrexia syndrome (25; 115) and may even provoke this syndrome. A case report describes parkinsonism-hyperpyrexia syndrome in a Parkinson disease patient treated with only bilateral subthalamic nucleus deep brain stimulation (STN-DBS). Deep brain stimulation was discontinued due to stimulation-related side effects, and subsequently, a sudden onset of hyperpyrexia, rigidity and decreased consciousness occurred (49; 05). In general, provoking factors for parkinsonism-hyperpyrexia syndrome include concomitant use of neuroleptics, dehydration, hot temperatures, wearing-off phenomenon, infections, and changes in intestinal absorptions (ie, ileus). Treatment of parkinsonism-hyperpyrexia syndrome is mainly supportive, with admission to the ICU and reintroduction of dopaminergic therapy either orally, via nasogastric tube, via a transdermal route (rotigotine patch), or parenterally (levodopa 50 to 100 mg infused over 3 hours); this can be repeated until the patient tolerates oral medications (41). Bromocriptine (5 to 10 mg 3 times per day) and dantrolene sodium (10 mg/kg per day in 3 to 4 divided doses) may be added as adjuvant supportive therapy (94). The addition of methylprednisolone 1 g per day for two days was an effective adjuvant therapy in a small randomized control trial (98). Additionally, a case report suggests that electroconvulsive therapy may be efficacious in the treatment of refractory parkinsonism-hyperpyrexia syndrome (69). Complications include the development of rhabdomyolysis and subsequent renal failure. Aggressive intravenous fluid hydration is recommended to prevent these complications. Patients are at risk for disseminated intravascular coagulation and deep vein thromboses, which can increase morbidity and mortality (79). In general, maintenance of some dopaminergic therapy (ideally levodopa-based) during medication adjustments is an important consideration to prevent parkinsonism-hyperpyrexia syndrome. Furthermore, treatment of the autonomic symptoms is critical in achieving a favorable outcome (44).

Acute decompensation of parkinsonism

Disorders associated with parkinsonism are typically chronic neurodegenerative disorders with a gradual subacute progression; however, a sudden change in symptom control may lead to emergency room visits or hospitalization. In an analysis of the Nationwide Inpatient Sample (NIS) database, pneumonia, urinary tract infection, and septicemia were the most common causes of infection (65). Parkinsonism may worsen in the setting of general medical illness, most notably urinary tract infections, which may not always be symptomatic. A physician should always rule out infection and other medical comorbidities, such as metabolic disorders and occult malignancy, when there is an acute deterioration in parkinsonian symptoms. It is routine for patients with parkinsonism, especially in advanced stages, to have fluctuations of motor symptoms and periods of suboptimal control. Motor complications, falls, and hallucinations were also implicated in hospitalization for idiopathic Parkinson disease (53). In general, adjustments to the medication regimen will resolve the issue; however, it is important to first consider other causes for decompensation.

Acute and subacute subdural hematomas have been associated with marked deterioration of parkinsonism (ie, worsening of bradykinesia, gait and balance impairments, and confusion) (122). Patients with parkinsonism have gait and balance impairments, which significantly increase their risk for falls leading to traumatic subdural hematoma. A clinician should have a low threshold to obtain neuroimaging, specifically computerized tomography scan, even if a history of fall is not elicited. Early identification of this condition and surgical evacuation of hemorrhage can be lifesaving. Another cause of deterioration in gait and balance is a compressive spinal cord lesion (93).

Additionally, life-threatening onset of severe dyskinesias as a complication of dopamine therapy can occur. Two cases of hyperthermia, rhabdomyolysis, hallucinations, and confusion as associated with severe dyskinesias in a Parkinson patient (dyskinesia-hyperpyrexia syndrome) were reported in advanced Parkinson disease. Both improved with aggressive supportive therapy, and the gradual discontinuation of the dopamine agonist. Levodopa was continued for the duration of the syndrome (34; 06).

Respiratory compromise is rarely associated with parkinsonism, with the exception of multiple system atrophy. Multiple system atrophy is associated with an increased risk for sudden death from upper airway obstruction (12). The presence of snoring and intermittent nocturnal stridor is an early sign of vocal cord dysfunction. This is followed by an increased risk of developing sleep apnea due to central hypoventilation (70), and patients may present with snoring and stridor due to posterior cricoarytenoid muscle dysfunction (vocal cord abductor paresis) (09). These symptoms can be present without evidence of clinical laryngeal dysfunction, such as hoarseness or dysarthria. It is prudent to directly question a bed partner or caregiver. The presence of stridor has been associated with less than a 2-year survival, and the onset of daytime stridor is particularly ominous (101). Prompt referral to an otolaryngologist for a fiber optic laryngoscopy is required to determine if laryngeal dysfunction is present. Patients with evidence of partial abductor paresis are at increased risk for sudden death and require definitive treatment with tracheostomy (100). Those who decline tracheostomy can be treated with continuous positive air pressure (CPAP) at night (42). Despite these interventions, sudden death has been reported in patients even after tracheostomy placement (47).

Serotonin syndrome

Serotonin syndrome is an iatrogenic disorder arising from increased biological activity of serotonin mediated by brainstem 5HT2A receptors (33). Serotonin syndrome was first described by Oates in the 1960s in a patient treated with monoamine oxidase inhibitor (MAOI) monotherapy (82). Serotonin syndrome typically arises from an excessive accumulation of serotonin and occur in a dose-dependent manner. In current clinical practice, serotonin syndrome usually occurs in patients taking two or more drugs with serotonergic actions. Medication combinations such as serotonin reuptake inhibitors with nonselective MAOIs and tricyclic antidepressants are typical offending agents. A single case of abrupt withdrawal of clozapine, a serotonin receptor antagonist, in the setting of continued administration of a selective serotonin reuptake inhibitor has been reported (103). However, other medications and illicit substances such as dextromethorphan, lithium, meperidine, fentanyl, tramadol, atypical neuroleptics, linezolid, triptans, dietary supplements, and recreational drugs such as ecstasy can significantly increase the risk of serotonin syndrome (see Table 2) (94; 43; 88; 55; 11). Though nonselective MAOIs are rarely used today, there is still some risk of serotonin syndrome, even with selective MAOIs (26). The risk of serotonin syndrome from combinations between triptans and selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors has been debated (33). In a registry study of nearly 48,000 patients prescribed triptans, the incidence of serotonin syndrome among those also taking selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors was found to be very low, ranging from 0 to 4 cases per 10,000 person-years (84). Despite a 2006 United States Food and Drug Administration warning about the risk of serotonin syndrome with these drug combinations, it has been proposed that serotonin syndrome is rare and may not warrant avoiding effective treatment for patients with coexisting affective disorders and migraines.

Table 2. Drugs Associated with Serotonin Syndrome

• 3,4 Methylenedioxymethamphetamine (MDMA or ecstasy)
• Amphetamines
• Atypical neuroleptics
• Buspirone hydrochloride
• Cocaine
• Dextromethorphan
• Dietary supplements: ginseng, St. John’s wort
• Linezolid
• Lithium
• L-tryptophan
• Lysergic acid diethylamide (LSD)
• Methylene blue
• Monoamine oxidase inhibitors
• Opiates (except morphine)
• Selective serotonin reuptake inhibitors
• Serotonin-norepinephrine reuptake inhibitors
• Tramadol
• Tricyclic antidepressants
• Triptans

Serotonin syndrome encompasses a spectrum of clinical features, many of which overlap with those of neuroleptic malignant syndrome. High levels of central serotonin lower central dopamine levels, which may lead to a hypodopaminergic state similar to neuroleptic malignant syndrome (94). Core symptoms include fever, myoclonus, and altered mental status (elevated mood, restlessness, disorientation).

Serotonin syndrome

This video demonstrates a woman with serotonin syndrome from the use of sertraline and trazodone. There are prominent myoclonic jerks involving facial muscles, as well as bilateral upper (not shown) and lower extremities. (Contrib...

Additional signs include hyperreflexia and clonus, rigidity, clonus, tachycardia, diaphoresis, and seizures. Hyperreflexia, clonus, and myoclonus are important features that can help differentiate serotonin syndrome from neuroleptic malignant syndrome. At least three distinct sets of diagnostic criteria exist for identifying serotonin syndrome, namely the Sternbach criteria, Radomski criteria, and Hunter criteria (121). The Sternbach criteria allow for identification of at-risk patients with milder symptoms (see Table 3). Unlike neuroleptic malignant syndrome, serotonin syndrome frequently resolves in 24 hours, but mortality is as high as 11% (112). Complications include disseminated intravascular coagulation, rhabdomyolysis, metabolic acidosis, renal failure, or respiratory failure (32).

Table 3. Sternbach Diagnostic Criteria for Serotonin Syndrome

	• Agitation • Diaphoresis • Diarrhea • Fever • Hyperreflexia • Incoordination • Mental status changes (confusion, hypomania) • Myoclonus • Shivering • Tremor
A. At least three of the following clinical features are present: in the setting of, coincident addition of, or increase in the dosage of a known serotonergic agent to an established medication regimen.
B. Other etiologies (ie, infection, metabolic, substance abuse, or withdrawal) have been ruled out.
C. A neuroleptic has not been started or increased in dosage prior to the onset of signs and symptoms listed above.
(102)

Early recognition of serotonin syndrome is important. Patients with mild symptoms of serotonin syndrome and effective control of mood disorder should not have a second serotonergic medication added to their regimen. A clinical pharmacist may be able to identify at risk patients and prevent the addition of another serotonergic medication that may exacerbate this syndrome (52). In more severe presentations, treatment is primarily supportive, with admission to the ICU and discontinuation of the offending medication. It is important not to add new medications with serotonergic action (see Table 2). Medications such as propranolol, diphenhydramine, chlorpromazine, diazepam, and methysergide have been used to treat serotonin syndrome. Cyproheptadine (12 mg starting dose, followed by 2 mg every two hours until appropriate clinical response), a 5HT2A antagonist and antihistamine, can reverse clinical symptoms in hours and may be initiated prophylactically when the addition of a third serotoninergic agent is required in specific circumstances (07; 23). Of note, with the increased use of atypical antipsychotics in combination with multiple serotonergic medications, a delayed presentation of serotonin syndrome and/or a mixed clinical presentation of serotonin syndrome and neuroleptic malignant syndrome may occur (61; 104). Transitioning from one selective serotonin reuptake inhibitor to another or to an MAOI should be approached carefully to prevent serotonin syndrome, particularly when switching from an SSRI with a prolonged elimination half-life such as fluoxetine, which may require five weeks or more for sufficient washout (51).

Malignant catatonia

Catatonia is a syndrome characterized by extreme negativism, motor immobility alternating with agitation, and behavioral abnormalities closely associated with developmental, mood, psychotic, toxic, and somatic disorders in children and adults (123). Malignant catatonia is a potentially lethal complication with a presentation similar to neuroleptic malignant syndrome (rigidity, fever, and obtundation), without a history of exposure to dopamine receptor-blocking medication. Malignant catatonia typically begins with intense agitation, catatonia, stereotypies, psychosis, and autonomic instability.

Malignant catatonia

This video demonstrates a woman with malignant catatonia. The first part demonstrates “catalepsy” in which the patient passively adopts the new posture after the examiner elevates her right arm. The second part demonstrates “po...

Other clinical features include motor symptoms (waxy flexibility, freezing, and stereotypies), abnormal speech (perseveration, echolalia, or mutism), reduced function (loss of independent activities of daily living), negativism (senseless refusal to comply), and reduced food and fluid intake. Frequently underdiagnosed, catatonia is a relatively common condition among psychiatric patients, with a reported frequency of 10% to 13%, and even higher rates in at-risk populations such as pervasive developmental and dysthymic disorders (17), and is often misdiagnosed as neuroleptic malignant syndrome in the ICU (96). In a study of 1719 schizophrenia patients admitted to an inpatient psychiatric facility with comorbid medical complications, catatonic patients had a 4-fold higher mortality risk than those without catatonic symptoms (31). Catatonia is frequently observed in the context of psychiatric conditions, particularly mood and psychotic disorders, but it can also manifest in less common clinical scenarios. These include autoimmune encephalitis, such as anti-NMDA receptor encephalitis (14), or as a result of withdrawal from certain medications, such as clozapine (110). Though the etiology of catatonia is unknown, low gamma-aminobutyric acid (GABA) activity in the frontal cortex in combination with low dopamine activity in the basal ganglia and/or elevated glutamatergic activity in the parietal cortex has been hypothesized. The abnormal neurotransmission has a widespread effect, which contributes to the broad range of clinical features in catatonia and may be associated with sudden discontinuation of dopamine receptor blocking agents (13). Additionally, the anterior thalamus has been implicated in malignant catatonia (83).

On average, malignant catatonia symptoms may last eight days, with temperatures as high as 110°F, followed by severe rigidity and lack of movements, stupor, and death (93). It is important to recognize malignant catatonia as a distinct syndrome in order to initiate appropriate therapy, which can result in complete resolution of symptoms within hours to days (28). Several diagnostic criteria have been proposed and are effective in screening patients for possible catatonia with high sensitivity. Unfortunately, most of these scales are not specific in establishing the diagnosis of malignant catatonia (see Table 4) (106).

Table 4. DSM V Criteria for the Diagnosis of Catatonia

	(1) Catalepsy - the individual maintains a fixed/frozen posture
	(2) Waxy flexibility - slight, even resistance to bodily manipulation
	(3) Stupor - no conscious mental activity is witnessed within the person’s environment
	(4) Agitation - emotionally restless; not as a result of external stimuli
	(5) Mutism - little to no verbal response; cannot be explained by aphasia
	(6) Negativism - opposition or unresponsiveness to external stimuli or instructions
	(7) Posturing - spontaneous and active maintenance of a posture against gravity
	(8) Mannerism - exaggerated or repetitive gestures or expressions
	(9) Stereotypies - repetitive movements without obvious purpose
	(10) Grimacing - displaying contorted facial expressions
	(11) Echolalia - mimics another’s speech
	(12) Echopraxia - mimics another’s movements
*3 or more symptoms are required to make the diagnosis
(106)

Several published reports have demonstrated the efficacy of low-dose benzodiazepines (eg, intravenous lorazepam 0.5 to 2 mg) as both diagnostic and therapeutic agents. If symptoms of catatonia improve, the benzodiazepines should be continued until the resolution of symptoms is complete. Oral zolpidem and electroconvulsive therapy have also been reported to be effective in the management of refractory malignant catatonia symptoms (108; 128). Studies have also demonstrated that N-methyl-D-aspartate receptor (NMDA) antagonists such as memantine, amantadine, and ketamine can improve symptoms of malignant catatonia (81; 16; 83; 08). The use of atypical neuroleptics is controversial. Several studies failed to demonstrate improvement of symptoms, with an additional risk for developing neuroleptic malignant syndrome (116; 83); only one study showed mild improvement (89). In general, neuroleptics are not recommended in the treatment of malignant catatonia.

Dystonic storm

Dystonia is a movement disorder characterized by sustained muscle contractions causing irregular movements and postures. Patients with primary or secondary generalized dystonia can develop an unremitting life-threatening spasm called “status dystonicus” or “dystonic storm” (46). The incidence, prevalence, and pathogenesis are unknown. Dystonic storm can be triggered by infections, medication adjustments, hyperthermia, trauma, dehydration, or respiratory compromise. There has been a significant increase in the number of reported episodes of dystonic storm, with cases more frequently associated with complications from deep brain stimulation, particularly battery exhaustion, rather than medication changes (62). This trend is likely influenced by advancements in the identification of genetic etiologies of dystonia, exemplified by conditions such as GNAO1, which are amenable to deep brain stimulation therapy. These unrelenting spasms lead to hyperpyrexia, dehydration, respiratory failure, and rhabdomyolysis with renal failure. Thus, patients should be admitted to the ICU for close monitoring. In general, spasms are refractory to medications that are typically used treat dystonia, such as anticholinergics (trihexyphenidyl), oral baclofen, and dopamine blockers or dopamine depleters, such as tetrabenazine (66; 44; 45; 03). Chloral hydrate and clonidine can be considered in children with dystonic storm to reduce dystonic spasms by facilitating sedation without respiratory depression (63). Benzodiazepines can be effective in suppressing spasms; however, this medication can cause respiratory depression and should be used with caution (66). Refractory cases may require general anesthesia, paralyzing agents, and intrathecal baclofen (22; 40). Case reports of pallidotomy and bilateral deep brain stimulation of the globus pallidus pars intrainterna (GPi) or subthalamic nucleus (STN) may be useful in intractable cases (78; 04; 35; 03; 107; 10). There has been a paradigm shift toward considering neurosurgical interventions, such as deep brain stimulation, earlier in the treatment of severe dystonic storms, particularly for patients with DYT1 generalized dystonia or other primary dystonias, rather than reserving them as a last-resort option (109).

Malignant Tourette syndrome

Tourette syndrome is a common neuropsychiatric disorder that presents with motor and phonic tics in childhood, in combination with comorbid attention deficit disorder and obsessive-compulsive behavior. The pathophysiology is largely unknown, though basal ganglia dopaminergic dysfunction has been implicated. Symptoms of Tourette syndrome naturally fluctuate throughout its clinical course, and most patients experience some degree of remission by the end of adolescence. In rare cases, Tourette syndrome and its comorbid behavioral symptoms can result in potentially life-threatening complications secondary to severe tics (ie, self-injurious tics, coprolalia, and copropraxia), extreme rage attacks, depression with suicidal ideation, and disabling self-injurious behaviors, which has been termed “malignant Tourette syndrome” (19). Additionally, violent dystonic neck tics can result in myelopathy (57; 111). These symptoms are difficult to treat with typical medications for tic suppression (ie, dopamine receptor blocking agents, and dopamine depleters) or behavioral management (SSRIs and other mood stabilizers). Botulinum toxin injections can be effective in reducing focal disabling tics such as dystonic neck tics (02), and a case report of laryngeal injections demonstrated reduction of coprolalia (99). For refractory cases of malignant Tourette syndrome, deep brain stimulation appears to be a promising treatment for tic reduction. The ideal stimulation target, globus pallidus pars interna (GPi) versus centromedian-parafascicular (CM-Pf) complex of the thalamus, continues to be debated (01; 68; 119; 76). A case of tics status was reported in a patient who developed continuous disabling vocal and motor tics on premature withdrawal of medications. These tics caused pain and disrupted sleep, later resulting in mild hyperthermia, tachycardia, and rhabdomyolysis, which required intravenous sedation. The patient required five days of sedation with ventilation before tics remitted to baseline (56).

Media

References

01: Ackermans L, Duits A, van der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 2011;134(Pt 3):832-44. PMID 21354977
02: Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, Pascual-Sedano B, Gironell A, Kulisevsky J. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord 2008;14(5):443-5. PMID 18337152
03: Allen, NM, Lin, JP, Lynch T, King MD. Status dystonicus: a practice guide. Dev Med Child Neurol 2014;56(2), 105-12. PMID 24304390
04: Apetauerova D, Schirmer CM, Shils JL, Zani J, Arle JE. Successful bilateral deep brain stimulation of the globus pallidus internus for persistent status dystonicus and generalized chorea. J Neurosurg 2010;113(3):634-8. PMID 20170298
05: Artusi CA, Merola A, Espay AJ, et al. Parkinsonism-hyperpyrexia syndrome and deep brain stimulation. J Neurol 2015;262(12):2780-2. PMID 26530506
06: Baek MS, Lee HW, Lyoo CH. A patient with recurrent dyskinesia and hyperpyrexia syndrome. J Mov Disord 2017;10(3):154-7. PMID 28704983
07: Baigel GD. Cyproheptadine and the treatment of an unconscious patient with the serotonin syndrome. Eur J Anaesthesiol 2003;20(7):586-8. PMID 12884999
08: Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28(4):543-7. PMID 23400857
09: Bannister R, Gibson W, Michaels L, Oppenheimer DR. Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain 1981;104(2):351-68. PMID 7237099
10: Barbosa BJAP, Carra RB, Duarte KP, et al. Bilateral subthalamic nucleus stimulation in refractory status dystonicus. J Neurol Sci 2018;388:159-61. PMID 29627014
11: Bartlett D. Drug-induced serotonin syndrome. Crit Care Nurse 2017;37(1):49-54. PMID 28148614
12: Benarroch EE. Brainstem respiratory control: substrates of respiratory failure of multiple system atrophy. Mov Disord 2007;22(2):155-61. PMID 17133520
13: Bibily J, McCollum B, de Leon J. Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review. Case Rep Psychiatry 2017;2017:2402731. PMID 28396815
14: Bogdan A, Askenazy F, Richelme C, Gindt M, Thummler S, Fernandez A. Case report: anti-NMDAR encephalitis presenting with catatonic symptoms in an adolescent female patient with a history of traumatic exposure. Front Psychiatry 2022;13:784306. PMID 35153875
15: Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014;20(Suppl 1):S108-12. PMID 24262159
16: Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007;19(4):406-12. PMID 18070843
17: Chalasani P, Healy D, Morriss R. Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. Psychol Med 2005;35(11):1667-75. PMID 16219124
18: Chan LG, Lee J, Ng BT, Chua HC, Sim K, Lee EL. Rare neuropsychiatric sequelae following neuroleptic malignant syndrome: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1998-9. PMID 18727947
19: Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord 2007;22(12):1743-50. PMID 17566119
20: Cloud LJ, Jankovic J. Systemic disease and movement disorders, chapter 29. In: Burn DJ, ed. Movement Disorders, Oxford Textbooks in Clinical Neurology. Oxford: Oxford University Press, 2013:315-26.
21: Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep 2017;17(1):6. PMID 28168537
22: Dalvi A, Fahn S, Ford B. Intrathecal baclofen in the treatment of dystonic storm. Mov Disord 1998;13(3):611-2. PMID 9613767
23: Deardorff OG, Khan T, Kulkarni G, Doisy R, Loehr C. Serotonin syndrome: prophylactic treatment with cyproheptadine. Prim Care Companion CNS Disord 2016;18(4). PMID 27828700
24: Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses.] [Article in French] Ann Med Psychol (Paris) 1960;118(1):145-52. PMID 13815606
25: Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Mov Disord 2007;22(1):148-9. PMID 17080464
26: Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord 2011;26(4):766-7. PMID 21370275
27: Fiore S, Persichino L, Anticoli S, De Pandis MF. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report. Acta Biomed 2014;85(3): 281-4. PMID 25567468
28: Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010;12(3):180-5. PMID 20425278
29: Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985;254(19):2792-5. PMID 4057489
30: Frucht SJ. A brief introduction to movement disorders. In: Frucht SJ, ed. Movement disorder emergencies: diagnosis and treatment. New York: Humana Press, 2013:1-7.**
31: Funayama M, Takata T, Koreki A, Ogino S, Mimura M. Catatonic stupor in schizophrenic disorders and subsequent medical complications and mortality. Psychosom Med 2018;80(4):370-6. PMID 29521882
32: Garside S, Rosebush PI. Serotonin syndrome: not a benign toxidrome. CMAJ 2003;169(6):543. PMID 12975218
33: Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache 2010;50(2):264-72. PMID 19925619
34: Gil-Navarro S, Grandas F. Dyskinesia-hyperpyrexia syndrome: another Parkinson's disease emergency. Mov Disord 2010;25(15):2691-2. PMID 20721898
35: Grandas F, Fernandez-Carballal C, Guzman-de-Villoria J, Ampuero I. Treatment of dystonic storm with pallidal stimulation in a patient with PANK2 mutation. Mov Disord 2011;26(5):921-2. PMID 21425339
36: Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand 2017;135(5):398-408. PMID 28144982
37: Gurrera RJ, Caroff SN, Cohen, A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi model. J Clinic Psychiatry 2011;72(9):1222-8. PMID 21733489
38: Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 2017;37(1):67-71. PMID 2802711
39: Gurrera RJ, Velamoor V, Cernovsky ZZ. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 2013. [Withdrawn] PMID 23975210
40: Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord 2001;16(6):1201-2. PMID 11748766
41: Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord 2003;Suppl 1:S47-9. PMID 12735915
42: Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004;63(5):930-2. PMID 15365155
43: Iqbal MM, Basil MJ, Kaplan J, Iqbal MT. Overview of serotonin syndrome. Ann Clin Psychiatry 2012;24(4):310-8. PMID 23145389
44: Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8(9):844-56. PMID 19679276
45: Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11(11):1509-23. PMID 22014129
46: Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology 1982;32(10):1195-7. PMID 6889706
47: Jin K, Okabe S, Chida K, et al. Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 2007;68(19):1618-21. PMID 17485650
48: Kaasinen V, Joutsa J, Noponen T, Päivärinta M. Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol 2014;6(3):275-80. PMID 25566059
49: Kadowaki T, Hashimoto K, Suzuki K, Watanabe Y, Hirata K. Case report: recurrent parkinsonism-hyperpyrexia syndrome following discontinuation of subthalamic deep brain stimulation. Mov Disord 2011;26(8):1561-2. PMID 21449010
50: Kaino K, Kumagai R, Furukawa S, et al. Reversible splenial lesion syndrome with hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine. J Diabetes Investg 2017;8(3):392-4. PMID 27863115
51: Keks N, Hope J, Keogh S. Switching and stopping antidepressants. Aust Prescr 2016;39(3):76-83. PMID 27346915
52: Khalil V, Chin K, Tran M, Furtula D. The impact of pharmacists’ input to reduce serotonin syndrome drug interactions in an Australian hospital. Int J Evi Based Healthc 2016;14(3):123-9. PMID 27552535
53: Koay L, Rose J, Abdelhafiz AH. Factors that lead to hospitalization in patients with Parkinson disease-A systematic review. Int J Clin Pract 2018;72(1). PMID 29119656
54: Kouparanis A, Bozikas A, Spilioti M, Tziomalos K. Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: successful treatment with dantrolene. Brain Inj 2015;29(5):658-60. PMID 25625410
55: Koury KM, Tsui B, Gulur P. Incidence of serotonin syndrome in patients treated with fentanyl on serotonergic agents. Pain Physician 2015;18(1):E27-30. PMID 25675067
56: Kovacs N, Herold R, Janszky J, Komoly S, Nagy F. Tics status: a movement disorder emergency: observations. J Neurol 2011;258(1):143-5. PMID 20658244
57: Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord 1996;11(5):563-6. PMID 8866498
58: Labuda A, Cullen N. Brain injury following neuroleptic malignant syndrome: case report and review of the literature. Brain Inj 2006;20(7):775-8. PMID 16809210
59: Lenhard T, Kulkens S, Schwab S. Cerebral salt-wasting syndrome in a patient with neuroleptic malignant syndrome. Arch Neurol 2007;64(1):122-5. PMID 17210819
60: Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):1137-45. PMID 2863986
61: Little K, Lin CM, Reynolds RM. Delayed serotonin syndrome in the setting of a mixed fluoxetine and serotonin antagonist overdose. Am J Case Rep 2018;19:604-7. PMID 29795058
62: Lumsden DE, Cif L, Capuano A, Allen NM. The changing face of reported status dystonicus – A systematic review. Parkinsonism Relat Disord 2023;112:105438. PMID 37268557
63: Lumsden DE, King MD, Allen NM. Status dystonicus in childhood. Curr Opin Pediatr 2017;29(6):674-82. PMID 28937508
64: Lyons JL, Cohen AB. Selective Cerebellar and Basal Ganglia Injury in Neuroleptic Malignant Syndrome. J Neuroimaging 2013;23(2):240-1. PMID 21418121
65: Mahajan A, Balakrishnan P, Patel A, et al. Epidemiology of inpatient stay in Parkinson’s disease in the United States: Insights from Nationwide Inpatient Sample. J Clin Neurosci 2016;31:162-5. PMID 27242063
66: Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998;121(Pt 2):243-52. PMID 9549503
67: Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010;19(5):429-35. PMID 20306454
68: Martinez-Fernandez R, Zrinzo L, Aviles-Olmos I, et al. Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus. Mov Disord 2011;26(10):1922-30. PMID 21538528
69: Meagher LJ, McKay D, Herkes GK, Needham M. Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. J Clin Neurosci 2006;13(8):857-9. PMID 16914315
70: Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord 2010;16(10):628-38. PMID 20674459
71: Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Mov Disord 2012;27(14):1816-9. PMID 23208724
72: Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol 2013;12(6):597-608. PMID 23602779
73: Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes and mortality. Neurocrit Care 2016;24(1):97-103. PMID 26223336
74: Monte AA, Waksman JC. Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity. J Clin Psychopharmacol 2010;30(5):628-9. PMID 20841960
75: Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009;15 Suppl 3:S224-32. PMID 20082997
76: Motlagh MG, Smith ME, Landeros-Weisenberger A, et al. Lessons learned from open-label deep brain stimulation for Tourette Syndrome: eight cases over 7 years. Tremor Other Hyperkinet Mov (NY) 2013;3. PMID 24255802
77: Nagamine M, Yoshino A, Sakurai Y, Sanga M, Takahashi R, Nomura S. Exacerbating factors in neuroleptic malignant syndrome: comparisons between cases with death, sequelae, and full recovery. J Clin Psychopharmacol 2005;25(5):499-501. PMID 16160631
78: Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology 1991;41(7):1141-2. PMID 2067645
79: Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009;10(1):136-40. PMID 18712508
80: Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry 2012;57(8):512-8. PMID 22854034
81: Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia. Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry 1997;62(4):404-6. PMID 9120462
82: Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960;10:1076-8. PMID 13730138
83: Obregon DF, Velasco RM, Wuerz TP, Catalano MC, Catalano G, Kahn D. Memantine and catatonia: a case report and literature review. J Psychiatr Pract 2011;17(4):292-9. PMID 21775832
84: Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurology 2018;75(5):566-72. PMID 29482205
85: Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat 2017;13:161-75. PMID 28144147
86: Ozdemir I, Kuru E, Safak Y, Tulaci RG. A neuroleptic malignant syndrome with rigidity. Psychiatry Investg 2018;15(2):226-9. PMID 29475219
87: Pàmpols-Pérez S, Gisbert-Solà A, Resa-Pérez B, Jiménez-Mayoral A, Forcada-Pach I, Llorca-Bofi V. Neuroleptic malignant syndrome associated with lurasidone: a case report. J Clin Psychopharmacol 2023;43(6):548-9. PMID 37930214
88: Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants. J Pharm Pract 2014;27(1):71-8. PMID 24153222
89: Peralta V, Campos MS, de Jalon EG, Cuesta MJ. DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res 2010;118(1-3):168-75. PMID 20071147
90: Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012;24(2):155-62. PMID 22563571
91: Pfeiffer RF, Sucha EL. “On-off”-induced lethal hyperthermia. Mov Disord 1989;4(4):338-41. PMID 2811893
92: Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016;50(11):973-81. PMID 27423483
93: Poston KL, Frucht SJ. Movement disorder emergencies. J Neurol 2008;255 Suppl4:2-13.** PMID 18821080
94: Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies Part 1: Hypokinetic disorders. Arch Neurol 2011;68(5):567-72. PMID 21555633
95: Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50(8):295-8. PMID 2569457
96: Saddawi-Konefka D, Berg SM, Nejad SH, Bittner EA. Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. a case series and review of the literature. Crit Care Med 2014;42(3):e234-41. PMID 24275514
97: Sahin A, Cicek M, Gonenc Cekic O, et al. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. Turk J Emerg Med 2017;17(4):141-5. PMID 29464217
98: Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74(5):574-6. PMID 12700295
99: Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996;11(4):431-3. PMID 8813224
100: Shimohata TH, Shinoda H, Nakayama H, et al. Daytime hypoxemia, sleep-disordered breathing, and laryngopharyngeal findings in multiple system atrophy. Arch Neurol 2007;64(6):856-61. PMID 17562934
101: Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord 2000;15(4):699-704. PMID 10928581
102: Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148(6):705-13. PMID 2035713
103: Stevenson E, Schembri F, Green DM, Burns JD. Serotonin syndrome associated with clozapine withdrawal. JAMA Neurol 2013;70(8):1054-5. PMID 23753931
104: Sun C, Sweet H, Minns AB, Shapiro D, Jenkins W. A mixed presentation of serotonin vs neuroleptic malignant syndrome in a 12-year-old boy. Pediatr Emerg Care 2018;36(10):e589-91. PMID 29698346
105: Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9 Suppl 1:S31-41. PMID 12735913
106: Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. Schizophr Res 2013;150(1):26-30. PMID 23806583
107: Tanrikulu B, Ozen A, Gunal DI, et al. Deep brain stimulation as a treatment for dystonia storm in pantothenate kinase-associated neurodegeneration syndrome: case report of a patient with homozygous C.628 T>G mutation of PANK2 gene. Acta Neurochir (Wien) 2015;157(9):1513-6. PMID 26223911
108: Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003;160(7):1233-41. PMID 12832234
109: Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord 2017;4(1):10.** PMID 28461905
110: Thammongkolchai T, Termsarasab P. Catatonia secondary to clozapine withdrawal: A case report. J Neurol Sci 2023;455:120865. PMID 37952383
111: Thenganatt MA, Jankovic J. Recent advances in understanding and managing Tourette syndrome. F1000Res 2016;5. PMID 26918185
112: Thomas P, Maron M, Rascle C, Cottencin O, Vaiva G, Goudemand M. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry 1998;43(4):303-5. PMID 9513741
113: Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012;201(1):52-6. PMID 22626633
114: Tsutsumi Y, Yamamoto K, Matsuura S, Hata S, Sakai M, Shirakura K. The treatment of neuroleptic malignant syndrome using dantrolene sodium. Psychiatry Clin Neurosci 1998;52(4):433-8. PMID 9766694
115: Urasaki E, Fukudome T, Hirose M, Nakane S, Matsuo H, Yamakawa Y. Neuroleptic malignant syndrome (parkinsonism-hyperpyrexia syndrome) after deep brain stimulation of the subthalamic nucleus. J Clin Neurosci 2013;20(5):740-1. PMID 23465352
116: Van Den Eede F, Van Hecke J, Van Dalfsen A, Van den Bossche B, Cosyns P, Sabbe BG. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry 2005;20(5-6):422-9. PMID 15964746
117: van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. Psychopharmacol Bull 2019;49(1):84-91. PMID 30858642
118: Velosa A, Neves A, Barahona-Correa JB, Oliveira-Maia AJ. Neuroleptic malignant syndrome: a concealed diagnosis with multi treatment approach. BMJ Case Rep 2019;12(6):e225840. PMID 31213433
119: Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 2012;90(4):213-24. PMID 22699684
120: Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY) 2013;3. PMID 23858394
121: Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases. BMC Neurol 2016;16(1):97. PMID 27406219
122: Wiest RG, Burgunder JM, Krauss JK. Chronic subdural haematomas and Parkinsonian syndromes. Acta Neurochir (Wien) 1999;141(7):753-7; discussion 757-8. PMID 10481787
123: Wijemanne S, Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry 2015;86(8):825-32. PMID 25411548
124: Wittenauer Welsh J, Janjua AU, Garlow SJ, et al. Use of expert consultation in a case of neuroleptic malignant syndrome requiring electroconvulsive therapy. J Psychiatr Pract 2016;22(6):484-9. PMID 27824784
125: Yeh CT, Fu CH. A reversible isolated lesion in the splenium of corpus callosum in a patient with probable neuroleptic malignant syndrome—case report. Acta Neurol Taiwan 2015;24(3):87-91. PMID 27333832
126: Yildirim V, Direk MC, Gunes S, Okuyaz C, Toros F. Neuroleptic malignant syndrome associated with valproate in an adolescent. Clin Psychopharmacol Neurosci 2017;15(1):76-8. PMID 28138117
127: Zhang F, Kanzali P, Rubin V, Para C, Goldman J. Neuroleptic malignant syndrome with thyroid disorder: an unusual case report. Medicine 2017;96(39):e81919. PMID 28953679
128: Zisselman MH, Jaffe RL. ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 2010;167(2):127-32. PMID 20123920

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Pichet Termsarasab MD

Dr. Termsarasab of Ramathibodi Hospital, Mahidol University has no relevant financial relationships to disclose.
See Profile

Editor

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

Neepa Patel MD

ICD & OMIM codes

ICD-9: Neuroleptic malignant syndrome: 333.92

Other extrapyramidal diseases and abnormal movements: 333.99

Tourette syndrome: 307.23

Tics of organic origin: 333.3

Paralysis agitans: 332.0

Secondary parkinsonism: 332.1

Subdural hemorrhage following injury without mention of open intracranial wound with no loss of consciousness: 852.21

Other degenerative diseases of the basal ganglia: 333.0

Other specified transient organic mental disorders due to conditions classified elsewhere: 293.89
ICD-10: Neuroleptic malignant syndrome: G21.0

Other specified extrapyramidal and movement disorders: G25.89

Tourette disorder: F95.2

Other tics of organic origin: G25.61

Parkinson disease: G20

Neuroleptic-induced parkinsonism: G21.11

Other drug-induced secondary parkinsonism: G21.19

Other secondary parkinsonism: G21.8

Traumatic subdural hemorrhage without loss of consciousness, initial encounter: S06.5X0A

Other specified degenerative diseases of the basal ganglia: G23.8

Catatonic disorder due to known physiological condition: F06.1

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Movement disorder emergencies

Also Relevant

Acute drug-induced movement disorders
Catatonia
Deep brain stimulation in movement disorders
Malignant hyperthermia
Motor control of movement disorders
- Multiple system atrophy
- Neuroleptic malignant syndrome
- Parkinson disease
- Progressive supranuclear palsy
- Serotonin syndrome
- Tourette syndrome

Clinical Categories

Movement Disorders

Movement disorder emergencies …

Movement disorder emergencies

Introduction

Overview

Key points

Clinical features

Neuroleptic malignant syndrome

Table 1. Diagnostic Criteria and Associated Clinical Features and Laboratory Findings of Neuroleptic Malignant Syndrome

Parkinsonism-hyperpyrexia syndrome

Acute decompensation of parkinsonism

Serotonin syndrome

Table 2. Drugs Associated with Serotonin Syndrome

Table 3. Sternbach Diagnostic Criteria for Serotonin Syndrome

Malignant catatonia

Table 4. DSM V Criteria for the Diagnosis of Catatonia

Dystonic storm

Malignant Tourette syndrome

Media

References

Contributors

Author

Editor

Former Authors

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Movement disorder emergencies

Introduction

Overview

Key points

Clinical features

Neuroleptic malignant syndrome

Table 1. Diagnostic Criteria and Associated Clinical Features and Laboratory Findings of Neuroleptic Malignant Syndrome

Parkinsonism-hyperpyrexia syndrome

Acute decompensation of parkinsonism

Serotonin syndrome

Table 2. Drugs Associated with Serotonin Syndrome

Table 3. Sternbach Diagnostic Criteria for Serotonin Syndrome

Malignant catatonia

Table 4. DSM V Criteria for the Diagnosis of Catatonia

Dystonic storm

Malignant Tourette syndrome

Media

References

Contributors

Author

Editor

Former Authors

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.